Neuland Laboratories (NSE:NEULANDLAB) Total Receivables: ₹5,414 Mil (As of Mar. 2026)


NSE:NEULANDLAB Neuland Laboratories Ltd NSE:NEULANDLAB
90 GF Score
Price ₹18,579.00
GF Value ₹16,503.37
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Neuland Laboratories Total Receivables?

Neuland Laboratories NSE:NEULANDLAB +2.71% 90 Total Receivables is ₹5,414 Mil as of Mar. 2026. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 90/100 and a GF Value™ of ₹16,503.37 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Neuland Laboratories's Total Receivables for the quarter that ended in Mar. 2026 was ₹5,414 Mil.

Neuland Laboratories Total Receivables Related Terms

Neuland Laboratories Total Receivables Historical Data

* Premium members only.

The historical data trend for Neuland Laboratories's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuland Laboratories Total Receivables Chart

Neuland Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,414.80 3,718.67 3,830.36 3,241.96 5,413.53

Neuland Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,241.96 0.00 4,409.21 0.00 5,413.53
NSE:NEULANDLAB
90GF Score
Neuland Laboratories Ltd NSE:NEULANDLAB
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuland Laboratories Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ₹5,414 Mil mean?
Neuland Laboratories (NSE:NEULANDLAB) has a Total Receivables of ₹5,414 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Neuland Laboratories and its competitors.
Is Neuland Laboratories' Total Receivables too high?
Neuland Laboratories' current Total Receivables is ₹5,414 Mil. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Total Receivables compare to ZTS and UTHR?
Neuland Laboratories' Total Receivables of ₹5,414 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Neuland Laboratories and its competitors. Neuland Laboratories's current Total Receivables is ₹5,414 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,503.37, compared to a current price of ₹18,579.00 — trading 12.6% above its estimated fair value. The current Total Receivables is ₹5,414 Mil. Neuland Laboratories' overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Total Receivables is ₹5,414 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued. The current stock price of ₹18,579.00 is trading 12.6% above its estimated GF Value™ of ₹16,503.37. GuruFocus considers Neuland Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:NEULANDLAB:

  • Total Receivables: ₹5,414 Mil
  • GF Value™: ₹16,503.37 vs. price of ₹18,579.00 (12.6% above fair value)
  • GF Score™: 90/100 with 2 warning signs

No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuland Laboratories Business Description

Other Exchanges 524558:India
Address Road No. 82, Jubilee Hills, Plot No. 573A-III, Phoenix IVY Building, 11th Floor (5th Office Level), Hyderabad, TG, IND, 500033
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score

Get the complete analysis for NSE:NEULANDLAB

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹18,579.00
Price
₹16,503.37
GF Value